Cochrane Review Group
Sexually Transmitted Infections
16 systematic reviews in Sexually Transmitted Infections ask 191 questions. 19.9% have no studies to answer them, 27.7% rest on very low certainty evidence and 14.6% reach moderate or high certainty.
Reviews
16
Questions
191
current versions
No studies
19.9%
Moderate or high
14.6%
No studies 38 · 19.9%Ungraded 4 · 2.1%Very low 53 · 27.7%Low 68 · 35.6%Moderate 19 · 9.9%High 9 · 4.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Drug treatment vs placebo or no treatment Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis Treatment for recurrent vulvovaginal candidiasis (thrush) (2022) · Cochrane | no estimate extracted | 5 studies · 5 participants | Very low |
Oral drug treatment vs topical drug treatment Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis Treatment for recurrent vulvovaginal candidiasis (thrush) (2022) · Cochrane | RR 1.66 [0.83, 3.31] | 3 studies · 206 participants | Very low |
Oral drug treatment vs topical drug treatment Primary outcome 2: Clinical recurrence at 12 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis Treatment for recurrent vulvovaginal candidiasis (thrush) (2022) · Cochrane | RR 0.95 [0.71, 1.27] | 3 studies · 206 participants | Very low |
Oral drug treatment vs topical drug treatment Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis Treatment for recurrent vulvovaginal candidiasis (thrush) (2022) · Cochrane | no estimate extracted | 3 studies · 3 participants | Very low |
Intervention NR Serious adverse events · Heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | RR 1 [0.81, 1.24] | 3 studies · 4958 participants | Very low |
Intervention NR Acceptability · Heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Minor adverse events · Heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Herpes simplex virus · heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Gonorrhoea · Heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | RR 0.89 [0.67, 1.17] | 2 studies · 3069 participants | Very low |
Intervention NR Acceptability · Heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Minor adverse events · Heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Acceptability · heterosexual women Topical microbicides for preventing sexually transmitted infections (2021) · Cochrane | no estimate extracted | NR | No studies |
Reviews 16
Treatment for recurrent vulvovaginal candidiasis (thrush)
CochraneSoF table
8 questions
Topical microbicides for preventing sexually transmitted infections
CochraneSoF table
27 questions
Oral versus intra‐vaginal imidazole and triazole anti‐fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)
CochraneSoF table
9 questions
Antibiotic therapy for pelvic inflammatory disease
CochraneSoF table
37 questions
Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women
CochraneSoF table
17 questions
Antibiotic therapy for adults with neurosyphilis
CochraneSoF table
7 questions
Antibiotic treatment for newborns with congenital syphilis
CochraneSoF table
11 questions
Probiotics for vulvovaginal candidiasis in non‐pregnant women
CochraneSoF table
6 questions
Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults
CochraneSoF table
9 questions
Interventions for men and women with their first episode of genital herpes
CochraneSoF table
8 questions
Screening for genital chlamydia infection
CochraneSoF table
4 questions
Antibiotic treatment for the sexual partners of women with bacterial vaginosis
CochraneSoF table
12 questions
Home‐based versus clinic‐based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections
CochraneSoF table
4 questions
Imiquimod for anogenital warts in non‐immunocompromised adults
CochraneSoF table
17 questions
Strategies for partner notification for sexually transmitted infections, including HIV
CochraneSoF table
11 questions
Genital ulcer disease treatment for reducing sexual acquisition of HIV
CochraneSoF table
4 questions